NO20075696L - Nanopartikulaere preparater for kontrollert frigjoring omfattende syklosporin - Google Patents

Nanopartikulaere preparater for kontrollert frigjoring omfattende syklosporin

Info

Publication number: NO20075696L
Authority: NO; Norway
Prior art keywords: cyclosporin; controlled release; nanoparticulate; nanoparticulated; composition
Prior art date: 2005-04-12

Application number

NO20075696A

Other languages

English (en)

Norwegian (no)

Inventor

Gary Liversidge

Scott Jenkins

Original Assignee

Elan Pharma Int Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-12

Filing date

2007-11-07

Publication date

2008-01-03

2007-11-07 Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd

2008-01-03 Publication of NO20075696L publication Critical patent/NO20075696L/no

Links

PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title abstract 5
229930105110 Cyclosporin A Natural products 0.000 title abstract 5
108010036949 Cyclosporine Proteins 0.000 title abstract 5
229960001265 ciclosporin Drugs 0.000 title abstract 5
229930182912 cyclosporin Natural products 0.000 title abstract 5
239000003405 delayed action preparation Substances 0.000 title 1
208000023275 Autoimmune disease Diseases 0.000 abstract 2
201000004681 Psoriasis Diseases 0.000 abstract 2
206010052779 Transplant rejections Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
210000000056 organ Anatomy 0.000 abstract 2
239000002245 particle Substances 0.000 abstract 2
230000002265 prevention Effects 0.000 abstract 2
206010039073 rheumatoid arthritis Diseases 0.000 abstract 2
230000002902 bimodal effect Effects 0.000 abstract 1
238000013270 controlled release Methods 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Transplantation (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20075696A 2005-04-12 2007-11-07 Nanopartikulaere preparater for kontrollert frigjoring omfattende syklosporin NO20075696L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US67083605P	2005-04-12	2005-04-12
PCT/US2006/013631 WO2006110802A1 (fr)	2005-04-12	2006-04-12	Compositions nanoparticulaires a liberation controlee et a teneur en cyclosporine

Publications (1)

Publication Number	Publication Date
NO20075696L true NO20075696L (no)	2008-01-03

Family

ID=37087359

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20075696A NO20075696L (no)	2005-04-12	2007-11-07	Nanopartikulaere preparater for kontrollert frigjoring omfattende syklosporin

Country Status (14)

Country	Link
US (2)	US7825087B2 (fr)
EP (1)	EP1868582A4 (fr)
JP (1)	JP2008535921A (fr)
KR (1)	KR20080007580A (fr)
CN (1)	CN101171000A (fr)
AU (1)	AU2006235478B2 (fr)
BR (1)	BRPI0609071A2 (fr)
CA (1)	CA2603084A1 (fr)
EA (1)	EA200702216A1 (fr)
IL (1)	IL186469A0 (fr)
MX (1)	MX2007012762A (fr)
NO (1)	NO20075696L (fr)
WO (1)	WO2006110802A1 (fr)
ZA (1)	ZA200708260B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7825087B2 (en) *	2005-04-12	2010-11-02	Elan Pharma International Limited	Nanoparticulate and controlled release compositions comprising cyclosporine
CA3027598C (fr) *	2007-01-10	2020-07-21	Board Of Regents The University Of Texas System	Administration amelioree de compositions medicamenteuses immunosuppressives par voie pulmonaire
EP2380564B1 (fr)	2007-04-04	2014-10-22	Sigmoid Pharma Limited	Composition pharmaceutique orale
CA2991390A1 (fr)	2009-02-09	2010-08-12	Cellutech Ab	Coques celluloses
EP2396070B1 (fr)	2009-02-12	2024-12-04	Incept Llc	Délivrance de médicament par bouchons d'hydrogels
CN105213318A (zh)	2009-05-18	2016-01-06	希格默伊德药业有限公司	包含油滴的组合物
EP3167875A1 (fr) *	2009-05-27	2017-05-17	Alkermes Pharma Ireland Limited	Réduction d'agrégation de type paillettes dans des compositions de meloxicam nanoparticulaire
CN102573802A (zh)	2009-08-12	2012-07-11	希格默伊德药业有限公司	包含聚合物基质和油相的免疫调节组合物
US9012511B2 (en)	2010-05-19	2015-04-21	Alkermes Pharma Ireland Limited	Nanoparticulate cinacalcet compositions
GB201020032D0 (en)	2010-11-25	2011-01-12	Sigmoid Pharma Ltd	Composition
CN103282044B (zh) *	2010-12-28	2016-07-06	韩林制药株式会社	纳米乳剂形态的眼科用组合物
GB201100786D0 (en) *	2011-01-18	2011-03-02	Ems Sa	Pharmaceutical compositions of immunosuppressants
US8287903B2 (en)	2011-02-15	2012-10-16	Tris Pharma Inc	Orally effective methylphenidate extended release powder and aqueous suspension product
US10226417B2 (en)	2011-09-16	2019-03-12	Peter Jarrett	Drug delivery systems and applications
EP3613413A1 (fr)	2011-12-05	2020-02-26	Incept, LLC	Procédés d'organogel médical et compositions
JP6382187B2 (ja) *	2012-06-21	2018-08-29	フォスフォレックス，インコーポレーテッド	インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
GB201212010D0 (en)	2012-07-05	2012-08-22	Sigmoid Pharma Ltd	Formulations
GB201222455D0 (en) *	2012-12-13	2013-01-30	Perioc Ltd	Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
GB201304662D0 (en)	2013-03-14	2013-05-01	Sigmoid Pharma Ltd	Compositions
GB201319792D0 (en) *	2013-11-08	2013-12-25	Sigmoid Pharma Ltd	Formulations
GB201319791D0 (en)	2013-11-08	2013-12-25	Sigmoid Pharma Ltd	Formulations
US20150352176A1 (en) *	2014-06-06	2015-12-10	Newport Research, Inc.	Oil-free and fat-free aqueous suspensions of cyclosporin
CN104717963B (zh) *	2014-09-22	2016-12-14	江苏大学	一种双层包衣的环孢素a缓释微丸制剂及其制备方法
DK3215127T3 (da)	2014-11-07	2021-02-01	Sublimity Therapeutics Ltd	Sammensætninger omfattende cyclosporin
US11324800B2 (en)	2015-01-15	2022-05-10	Wellspring Ophthalmics, Inc.	Aqueous suspensions of cyclosporin
US20200237859A1 (en)	2019-01-25	2020-07-30	Newport Research, Inc.	Aqueous suspensions of cyclosporin
JP2018524287A (ja)	2015-05-27	2018-08-30	ユニバーシティーオブピッツバーグ − オブザコモンウェルスシステムオブハイヤーエデュケーション	造影後の膵炎のリスクを低下させるための組成物及び方法
US10525012B2 (en)	2015-08-11	2020-01-07	Eyesiu Medicines B.V.	Pegylated lipid nanoparticle with bioactive lipophilic compound
KR102146704B1 (ko) *	2018-04-13	2020-08-21	가천대학교 산학협력단	사이클로스포린 A (CsA) 경피 및 피내 약물전달용 마이크로구조체
CN110779787B (zh) *	2019-11-15	2022-04-29	北京丹大生物技术有限公司	一种环孢霉素全血样本的前处理剂及其使用方法
WO2024019118A1 (fr) *	2022-07-20	2024-01-25	旭化成株式会社	Composition de médicament à dérivé d'acide hyaluronique et composition de médicament
US12303604B1 (en)	2024-10-16	2025-05-20	Currax Pharmaceuticals Llc	Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4826689A (en) *	1984-05-21	1989-05-02	University Of Rochester	Method for making uniformly sized particles from water-insoluble organic compounds
US5639724A (en)	1984-07-24	1997-06-17	Sandoz Ltd.	Cyclosporin galenic forms
US4783484A (en) *	1984-10-05	1988-11-08	University Of Rochester	Particulate composition and use thereof as antimicrobial agent
US4825589A (en) *	1987-03-09	1989-05-02	Straw Jesse H	Hanging plant carrier
US5756450A (en) *	1987-09-15	1998-05-26	Novartis Corporation	Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
FR2659234B1 (fr) *	1990-03-12	1994-07-01	Fileco Sa	Composition therapeutique contenant un compose phenol et de la propolis utile contre les virus a capside lipidique, notamment les virus de l'herpes.
US5552160A (en) *	1991-01-25	1996-09-03	Nanosystems L.L.C.	Surface modified NSAID nanoparticles
US5399363A (en) *	1991-01-25	1995-03-21	Eastman Kodak Company	Surface modified anticancer nanoparticles
US5145684A (en) *	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
AU642066B2 (en) *	1991-01-25	1993-10-07	Nanosystems L.L.C.	X-ray contrast compositions useful in medical imaging
JPH06511481A (ja)	1991-07-05	1994-12-22	ユニバーシティオブロチェスター	気泡を取り込む超微小非凝集多孔質粒子
SG45449A1 (en)	1992-05-13	1998-01-16	Sandoz Ltd	Ophthalmic compositions
NZ248813A (en) *	1992-11-25	1995-06-27	Eastman Kodak Co	Polymeric grinding media used in grinding pharmaceutical substances
US5349957A (en) *	1992-12-02	1994-09-27	Sterling Winthrop Inc.	Preparation and magnetic properties of very small magnetite-dextran particles
US5298262A (en) *	1992-12-04	1994-03-29	Sterling Winthrop Inc.	Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) *	1992-12-04	1994-09-13	Sterling Winthrop Inc.	Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5302401A (en) *	1992-12-09	1994-04-12	Sterling Winthrop Inc.	Method to reduce particle size growth during lyophilization
US5340564A (en) *	1992-12-10	1994-08-23	Sterling Winthrop Inc.	Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) *	1992-12-11	1994-08-09	Sterling Winthrop Inc.	Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) *	1992-12-15	1995-07-04	Eastman Kodak Company	Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) *	1992-12-16	1994-10-04	Sterling Winthrop Inc.	Use of purified surface modifiers to prevent particle aggregation during sterilization
US5326552A (en) *	1992-12-17	1994-07-05	Sterling Winthrop Inc.	Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5401492A (en) *	1992-12-17	1995-03-28	Sterling Winthrop, Inc.	Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
US5264610A (en) *	1993-03-29	1993-11-23	Sterling Winthrop Inc.	Iodinated aromatic propanedioates
US5718388A (en)	1994-05-25	1998-02-17	Eastman Kodak	Continuous method of grinding pharmaceutical substances
TW384224B (en)	1994-05-25	2000-03-11	Nano Sys Llc	Method of preparing submicron particles of a therapeutic or diagnostic agent
US5525328A (en) *	1994-06-24	1996-06-11	Nanosystems L.L.C.	Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging
US5587143A (en) *	1994-06-28	1996-12-24	Nanosystems L.L.C.	Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
SK164796A3 (en)	1994-11-03	1997-06-04	Dresden Arzneimittel	Novel cyclosporine preparation forms for oral administration of and process for producing them
US5585108A (en) *	1994-12-30	1996-12-17	Nanosystems L.L.C.	Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5628981A (en)	1994-12-30	1997-05-13	Nano Systems L.L.C.	Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5466440A (en) *	1994-12-30	1995-11-14	Eastman Kodak Company	Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5665331A (en)	1995-01-10	1997-09-09	Nanosystems L.L.C.	Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5662883A (en)	1995-01-10	1997-09-02	Nanosystems L.L.C.	Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5560932A (en) *	1995-01-10	1996-10-01	Nano Systems L.L.C.	Microprecipitation of nanoparticulate pharmaceutical agents
US5569448A (en) *	1995-01-24	1996-10-29	Nano Systems L.L.C.	Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5560931A (en) *	1995-02-14	1996-10-01	Nawosystems L.L.C.	Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en) *	1995-02-06	1996-11-05	Nano Systems L.L.C.	Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5593657A (en) *	1995-02-09	1997-01-14	Nanosystems L.L.C.	Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5534270A (en) *	1995-02-09	1996-07-09	Nanosystems Llc	Method of preparing stable drug nanoparticles
US5518738A (en) *	1995-02-09	1996-05-21	Nanosystem L.L.C.	Nanoparticulate nsaid compositions
US5622938A (en) *	1995-02-09	1997-04-22	Nano Systems L.L.C.	Sugar base surfactant for nanocrystals
US5500204A (en) *	1995-02-10	1996-03-19	Eastman Kodak Company	Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging
US5591456A (en) *	1995-02-10	1997-01-07	Nanosystems L.L.C.	Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) *	1995-02-13	1996-11-12	Nano Systems L.L.C.	Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) *	1995-02-14	1996-04-23	Nanosystems Llc	Process for preparing therapeutic compositions containing nanoparticles
US5543133A (en) *	1995-02-14	1996-08-06	Nanosystems L.L.C.	Process of preparing x-ray contrast compositions containing nanoparticles
US5580579A (en) *	1995-02-15	1996-12-03	Nano Systems L.L.C.	Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5565188A (en) *	1995-02-24	1996-10-15	Nanosystems L.L.C.	Polyalkylene block copolymers as surface modifiers for nanoparticles
EP0810853B1 (fr)	1995-02-24	2004-08-25	Elan Pharma International Limited	Aerosols contenant des dispersions de nanoparticules
US5718919A (en)	1995-02-24	1998-02-17	Nanosystems L.L.C.	Nanoparticles containing the R(-)enantiomer of ibuprofen
US5747001A (en)	1995-02-24	1998-05-05	Nanosystems, L.L.C.	Aerosols containing beclomethazone nanoparticle dispersions
US5573749A (en) *	1995-03-09	1996-11-12	Nano Systems L.L.C.	Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5472683A (en) *	1995-03-09	1995-12-05	Eastman Kodak Company	Nanoparticulate diagnostic mixed carbamic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5643552A (en)	1995-03-09	1997-07-01	Nanosystems L.L.C.	Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
GB9618952D0 (en)	1996-09-11	1996-10-23	Sandoz Ltd	Process
US5521218A (en) *	1995-05-15	1996-05-28	Nanosystems L.L.C.	Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
US5573750A (en) *	1995-05-22	1996-11-12	Nanosystems L.L.C.	Diagnostic imaging x-ray contrast agents
US5962019A (en)	1995-08-25	1999-10-05	Sangstat Medical Corporation	Oral cyclosporin formulations
US5766629A (en)	1995-08-25	1998-06-16	Sangstat Medical Corporation	Oral cyclosporin formulations
US5827822A (en)	1996-03-25	1998-10-27	Sangstat Medical Corporation	Cyclosporin a formulations as nanoparticles
US5834017A (en)	1995-08-25	1998-11-10	Sangstat Medical Corporation	Oral cyclopsporin formulations
US5834025A (en)	1995-09-29	1998-11-10	Nanosystems L.L.C.	Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
NZ333657A (en)	1996-07-30	2000-05-26	Novartis Ag	A pharmaceutical composition comprising cyclosporin A and 40-O-(2-hydroxyethyl)-rapamycin
ATE275963T1 (de)	1997-01-30	2004-10-15	Novartis Pharma Gmbh	Ölfreie pharmazeutische zusammensetzung welche cyclosporin enthält
WO1998035666A1 (fr)	1997-02-13	1998-08-20	Nanosystems Llc	Preparation de pastilles de naproxene nanoparticulaire
US6045829A (en)	1997-02-13	2000-04-04	Elan Pharma International Limited	Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
IT1289938B1 (it)	1997-02-20	1998-10-19	Angelini Ricerche Spa	Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e
US6358425B1 (en)	1998-03-09	2002-03-19	Joseph A. King	Pool cleaning and sanitizing apparatus
US6153225A (en)	1998-08-13	2000-11-28	Elan Pharma International Limited	Injectable formulations of nanoparticulate naproxen
US6165506A (en)	1998-09-04	2000-12-26	Elan Pharma International Ltd.	Solid dose form of nanoparticulate naproxen
US8293277B2 (en) *	1998-10-01	2012-10-23	Alkermes Pharma Ireland Limited	Controlled-release nanoparticulate compositions
HU230454B1 (hu) *	1998-11-02	2016-07-28	Alkermes Pharma Ireland Limited	Metilfenidátot tartalmazó módosított felszabadulású sokszemcsés készítmény
US6428814B1 (en)	1999-10-08	2002-08-06	Elan Pharma International Ltd.	Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6375986B1 (en)	2000-09-21	2002-04-23	Elan Pharma International Ltd.	Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6270806B1 (en)	1999-03-03	2001-08-07	Elan Pharma International Limited	Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6267989B1 (en)	1999-03-08	2001-07-31	Klan Pharma International Ltd.	Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
GB9912476D0 (en)	1999-05-28	1999-07-28	Novartis Ag	Organic compounds
JP4156807B2 (ja)	1999-06-01	2008-09-24	エランファーマインターナショナル，リミティド	小型ミル及びその方法
US6273339B1 (en) *	1999-08-30	2001-08-14	Micron Technology, Inc.	Tamper resistant smart card and method of protecting data in a smart card
US6656504B1 (en) *	1999-09-09	2003-12-02	Elan Pharma International Ltd.	Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
DE60020382T2 (de) *	1999-09-21	2006-01-26	Skyepharma Canada Inc., Verdun	Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe
US6458849B1 (en) *	1999-09-23	2002-10-01	G.D. Searle & Co.	use of substituted N,N-disubstituted mercapto amino compounds for inhibiting cholesteryl ester transfer protein activity
US6316029B1 (en)	2000-05-18	2001-11-13	Flak Pharma International, Ltd.	Rapidly disintegrating solid oral dosage form
EP2283864A1 (fr) *	2002-07-16	2011-02-16	Elan Pharma International Ltd.	Composition liquide contenant des nanoparticules stabilisées d'une substance active
AU2003297260A1 (en) *	2002-11-12	2004-06-03	Elan Pharma International Ltd.	Fast-disintegrating solid dosage forms being not friable and comprising pullulan
MXPA05012467A (es) *	2003-05-19	2006-02-22	Baxter Int	Particulas solidas que comprenden un anticonvulsivo o un inmunosupresor revestido con uno o mas modificadores de superficie.
US7825087B2 (en) *	2005-04-12	2010-11-02	Elan Pharma International Limited	Nanoparticulate and controlled release compositions comprising cyclosporine

2006
- 2006-04-12 US US11/568,692 patent/US7825087B2/en not_active Expired - Fee Related
- 2006-04-12 WO PCT/US2006/013631 patent/WO2006110802A1/fr not_active Ceased
- 2006-04-12 JP JP2008506629A patent/JP2008535921A/ja not_active Withdrawn
- 2006-04-12 KR KR1020077026124A patent/KR20080007580A/ko not_active Withdrawn
- 2006-04-12 EP EP06749866A patent/EP1868582A4/fr not_active Withdrawn
- 2006-04-12 CN CNA2006800156761A patent/CN101171000A/zh active Pending
- 2006-04-12 BR BRPI0609071-0A patent/BRPI0609071A2/pt not_active IP Right Cessation
- 2006-04-12 AU AU2006235478A patent/AU2006235478B2/en not_active Expired - Fee Related
- 2006-04-12 EA EA200702216A patent/EA200702216A1/ru unknown
- 2006-04-12 MX MX2007012762A patent/MX2007012762A/es active IP Right Grant
- 2006-04-12 CA CA002603084A patent/CA2603084A1/fr not_active Abandoned
2007
- 2007-09-27 ZA ZA200708260A patent/ZA200708260B/xx unknown
- 2007-10-07 IL IL186469A patent/IL186469A0/en unknown
- 2007-11-07 NO NO20075696A patent/NO20075696L/no not_active Application Discontinuation
2010
- 2010-09-23 US US12/888,530 patent/US20110064800A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2008535921A (ja)	2008-09-04
US20080124389A1 (en)	2008-05-29
EP1868582A1 (fr)	2007-12-26
CN101171000A (zh)	2008-04-30
EA200702216A1 (ru)	2008-08-29
ZA200708260B (en)	2010-05-26
WO2006110802A1 (fr)	2006-10-19
CA2603084A1 (fr)	2006-10-19
US20110064800A1 (en)	2011-03-17
MX2007012762A (es)	2008-01-14
BRPI0609071A2 (pt)	2010-11-16
IL186469A0 (en)	2008-01-20
KR20080007580A (ko)	2008-01-22
AU2006235478B2 (en)	2011-07-21
EP1868582A4 (fr)	2011-06-22
AU2006235478A1 (en)	2006-10-19
US7825087B2 (en)	2010-11-02

Publication	Publication Date	Title
NO20075696L (no)	2008-01-03	Nanopartikulaere preparater for kontrollert frigjoring omfattende syklosporin
GB2453068A (en)	2009-03-25	Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells
WO2018175752A8 (fr)	2018-11-15	Compositions d'anticorps optimisées pour le traitement de troubles oculaires
ATE486618T1 (de)	2010-11-15	Medizinische vorrichtungen mit legierungen
WO2006002177A3 (fr)	2006-06-22	Anticorps anti-recepteur aux interferons alpha 1 et leurs utilisations
TW200716652A (en)	2007-05-01	Thienotriazolodiazepine compound and a medicinal use thereof
EA201290497A1 (ru)	2013-01-30	Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых
WO2011130675A3 (fr)	2012-02-23	Neurones dopaminergiques obtenus par différenciation de cellules souches pluripotentes et leurs utilisations
MY159551A (en)	2017-01-13	High affinity human antibodies to human protease-activated receptor-2
TW200700068A (en)	2007-01-01	Phthalazine, aza-and diaza-phthalazine compounds and methods of use
EP2213684A3 (fr)	2011-05-18	Anticorps nogo-a pour le traitement de la maladie d'Alzheimer
CA2821268C (fr)	2021-06-15	Anticorps monoclonal humain ayant une specificite pour la proteine e du virus de la dengue de serotype 1 et utilisations de celui-ci
EP4495059A3 (fr)	2025-03-26	Nanoparticules de silicium pour le traitement des maladies rénales
EA200700212A1 (ru)	2007-08-31	Многовалентные vla-4 антагонисты, содержащие полимерные фрагменты
GEP20257791B (en)	2025-09-10	Anti-cd30l antibodies and uses thereof
MA34642B1 (fr)	2013-11-02	Anticorps dirigé contre le tweak humain et leurs utilisations
MX2016005668A (es)	2016-10-28	Formas cristalinas de compuestos terapeuticos y sus usos.
ATE419236T1 (de)	2009-01-15	3,6-disubstituierte azabicyclo-3.1.0 hexan- derivate als muscarinische rezeptorantagonisten
WO2016011049A3 (fr)	2016-04-14	Compositions et procédés pour le traitement de maladies à l'aide de composés distribués sous forme de nanoparticules
WO2007076085A3 (fr)	2007-08-23	Pyrimidones et thiopyrimidones fusionnees et leurs utilisations
NO20076628L (no)	2008-03-12	Nanopartikkulaere sammensetninger med kontrollert frigjoring som omfatter arylheterosykliske forbindelser
WO2007140011A3 (fr)	2008-08-21	Cellules progénitrices érythroïdes et procédés de production du parvovirus b19 dans ces cellules
WO2008100621A3 (fr)	2008-12-11	Modulateurs de la cathepsine s au thioéther de tétrahydro-pyrazolo-pyridine
MX2023005346A (es)	2023-05-22	Anticuerpo biespecifico anti-tspan8/anti-cd3 y anticuerpo anti-tspan8.
WO2007076087A3 (fr)	2007-11-08	Quinazolones d'aryle substitue et leurs utilisations

Legal Events

Date	Code	Title	Description
2012-11-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application